Network meta-analysis on proportion of patients achieved ACR20 and PASI75 response with reference to etanercept
| ACR20 response | PASI75 response | |
|---|---|---|
| 10mg Tofacitinib BID | 0.38 [0.12; 1.22] | 0.68 [0.13; 3.54] |
| 150mg Secukinumab | 0.64 [0.22; 1.90] | 0.49 [0.07; 3.19] |
| 20mg Apremilast BID | 0.18 [0.07; 0.49] | 0.39 [0.08; 1.83] |
| 300mg Secukinumab | 0.77 [0.21; 2.80] | 0.67 [0.10; 4.56] |
| 30mg Apremilast BID | 0.24 [0.09; 0.63] | 0.48 [0.10; 2.22] |
| 45mg Ustekinumab | 0.26 [0.09; 0.75] | 1.18 [0.15; 9.09] |
| 5mg Tofacitinib BID | 0.25 [0.08; 0.81] | 0.64 [0.12; 3.29] |
| 80mg Ixekizumab Q2w | 0.40 [0.12; 1.27] | 2.74 [0.49; 15.37] |
| 80mg Ixekizumab Q4w | 0.35 [0.11; 1.11] | 1.73 [0.32; 9.31] |
| 90mg Ustekinumab | 0.32 [0.11; 0.92] | 1.40 [0.18; 10.74] |
| Adalimumab | 0.33 [0.13; 0.86] | 0.77 [0.17; 3.50] |
| Certolizumab | 0.42 [0.12; 1.39] | NA |
| Etanercept (reference) | 1.00 | 1.00 |
| Golimumab | 0.93 [0.25; 3.40] | 3.51 [0.44; 28.22] |
| Infliximab | 0.74 [0.26; 2.12] | 5.97 [0.89; 40.22] |
| Placebo | 0.10 [0.04; 0.22] | 0.09 [0.03; 0.35] |
NA: not applicable.